Ardelyx (ARDX) Enterprise Value (2013 - 2026)
Ardelyx's (ARDX) quarterly Enterprise Value came in at -$238.1 million in Q1 2026, down 11.27% YoY from -$268.3 million in Q1 2025, and up 10.06% on a QoQ basis from -$264.7 million in Q4 2025.
Ardelyx (ARDX) Enterprise Value (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Enterprise Value data on file, last reported at -$238.1 million in Q1 2026.
- Quarterly Enterprise Value fell 11.27% year-over-year to -$238.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$238.1 million (down 11.27% YoY) and the FY2025 annual result came in at -$264.7 million, down 5.83% from the prior year.
- Enterprise Value climbed to -$238.1 million in Q1 2026, from -$264.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$81.0 million in Q2 2022 to a low of -$264.7 million in Q4 2025.
- A 5-year average of -$177.6 million and a median of -$186.0 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 52.85% — and 2023, when it slumped 82.16%.
- Tracing ARDX's Enterprise Value over 5 years: stood at -$123.9 million in 2022, then tumbled by 48.74% to -$184.3 million in 2023, then plunged by 35.7% to -$250.1 million in 2024, then fell by 5.83% to -$264.7 million in 2025, then grew by 10.06% to -$238.1 million in 2026.
- The last three Enterprise Value figures came in at -$238.1 million (Q1 2026), -$264.7 million (Q4 2025), and -$242.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -281.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -281.83 Mn |
| Mar 31, 2026 | -238.07 Mn |
| Dec 31, 2025 | -264.69 Mn |
| Sep 30, 2025 | -242.71 Mn |
| Jun 30, 2025 | -238.45 Mn |
| Mar 31, 2025 | -213.95 Mn |
| Dec 31, 2024 | -250.10 Mn |
| Sep 30, 2024 | -190.40 Mn |
| Jun 30, 2024 | -185.96 Mn |
| Mar 31, 2024 | -202.58 Mn |
| Dec 31, 2023 | -184.30 Mn |
| Sep 30, 2023 | -165.08 Mn |
| Jun 30, 2023 | -127.58 Mn |
| Mar 31, 2023 | -130.37 Mn |
| Dec 31, 2022 | -123.91 Mn |
| Sep 30, 2022 | -90.62 Mn |
| Jun 30, 2022 | -81.01 Mn |
| Mar 31, 2022 | -89.70 Mn |
| Dec 31, 2021 | -116.69 Mn |
| Sep 30, 2021 | -141.65 Mn |